DOCS vs TXG: Which Stock Is the Better Buy?
Doximity, Inc. and 10x Genomics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DOCS vs TXG, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Doximity, Inc. (DOCS) | 10x Genomics, Inc. (TXG) | |
|---|---|---|
| Market cap | $3.7B | $3.7B |
| Revenue (latest FY) | $644.86M | $642.82M |
| Net income (latest FY) | $196.05M | $-43.54M |
| Revenue growth (5y CAGR) | 25.5% | 16.6% |
| Net margin | 30.4% | -6.8% |
| Return on equity | 20.6% | -5.5% |
| P/E ratio | 20.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full DOCS vs TXG breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DOCS's full financials → Open TXG's full financials →More comparisons
Frequently asked questions
Which is bigger, DOCS or TXG?
10x Genomics, Inc. is larger by market capitalization — $3.7B versus $3.7B.
Which grows faster, DOCS or TXG?
Over the last five fiscal years, Doximity, Inc. grew revenue faster — 25.5%/yr versus 16.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.